Wednesday, 24 Apr 2019

You are here

GCA Relapse Risk High with Steroids

Prior to the introduction of tocilizumab to manage giant cell arteritis (GCA), glucocorticoids (GC) have been the mainstay of therapy, but has been limited by relapses in disease. A recent metanalysis shows that relapses occur in nearly half of patients and are related to the duration of therapy rather than the initial dose of GC.

A literature review found 34 studies (2,505 patients) from 8 RCTs of GCA patients only treated with GC.

The overall prevalence of relapse was 47.2%, higher in RCTS than observational studies (p<0.0001).

The relapse rate was higher in older studies, reflecting a reliance on GC to treat GCA.

Shorter GC regimens were also associated with higher relapse rates (17 studies, rate decrease of 1.7% for one additional month, p<0.001). The duration of GC therapy was shorter in RCTs (12.8 months) than observational studies (28.8 months).

Relapse was not affected by the duration of GC therapy, initial GC dose, duration of follow‐up, sex or age.

These results suggest that trial designs in GCA call for at least 12 months of GC therapy to adequately assess risk of relapse.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Improved Survival in Lupus

A longitudinal study of systemic lupus erythematosus (SLE) from the Toronto Lupus Clinic has shown that mortality has decreased over time.

The cohort incuded 1732 SLE patients followed between 1971 and 2013. The cause of death was gleaned from death certificates, autopsy reports, hospital records or the records of the family physicians.  

EULAR 2019 Update to Lupus Management

The goal of SLE treatment is remission or low disease activity and flare prevention. Hydroxychloroquine is recommended in all patients with lupus, at a dose not exceeding 5 mg/kg real body weight. Glucocorticoids (GC) should be minimised to less than 7.5 mg/day (prednisone equivalent). Appropriate initiation of immunomodulatory agents (methotrexate, azathioprine, mycophenolate) can be tailored to the clinical scenarios and may allow for tapering or discontinuation of GC.

Mortality Risk Factors in Systemic Sclerosis

A French cohort study of 625 systemic sclerosis (SStc) patients has found a significantly increased mortality risk that can be predicted by common clinical variables.

In addition to a multicenter prospective study, investigators performed a metanalysis on SSc standarized mortality ratios (SMR) and hazard ratios of prognosis factors.

Better Tests Ahead in Lupus

The advent of "big data" and "-omics" technologies offers hope that clinicians will soon have better diagnostics for systemic lupus erythematosus, rheumatologists here were told.

Presenting Features of Early SLE

What clinical features best identify early systemic lupus erythematosus (SLE) patients from mimics?  A multicenter, multinational study aimed to evaluate manifestations at disease onset and to compare early SLE manifestations to those of diseases mimicking SLE.